-
Use of artificial intelligence in medicines’ lifecycle
Use of artificial intelligence in medicines’ lifecycle
-
Use of artificial intelligence in medicines’ lifecycle
Use of artificial intelligence in medicines’ lifecycle
Draft reflection paper for public consultation on regulators’ views on artificial intelligence for the development, use and regulation of human and veterinary medicines
-
EU steps up action to prevent shortages of antibiotics
EU steps up action to prevent shortages of antibiotics
-
EU steps up action to prevent shortages of antibiotics
EU steps up action to prevent shortages of antibiotics
Joint statement from EMA, the European Commission and the Heads of Medicines Agencies (HMA)
-
Safety review ongoing for GLP-1 receptor agonists
Safety review ongoing for GLP-1 receptor agonists
-
Safety review ongoing for GLP-1 receptor agonists
Safety review ongoing for GLP-1 receptor agonists
EMA’s safety committee, the PRAC, is reviewing data on the risk of suicidal thoughts with medicines used for weight loss and for treating type 2 diabetes
-
End of COVID-19 regulatory flexibilities
End of COVID-19 regulatory flexibilities
-
End of COVID-19 regulatory flexibilities
End of COVID-19 regulatory flexibilities
EMA, EC and HMA are phasing out extraordinary regulatory flexibilities which were introduced during the pandemic to help address regulatory and supply challenges
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal